How far can this company go in solving the root cause of Parkinson's disease with stem cells? Wuhan currently has 22,000 confirmed ...
COLOMBO: Twenty years after the massive Indian Ocean tsunami wreaked havoc on Sri Lanka, some survivors are still trying to pick up the pieces. Those living in poorly-constructed settlements ...
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly—has added fuel to an already fiery debate over the ...
Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...
(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...
COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...
Despite hitting its primary endpoints, the Novo Nordisk REDEFINE 1 Phase III trial saw patients achieving a weight loss of 22.7% after 68 weeks on CariSema. Credit: Getty Images / Bloomberg Danish ...
Novo Nordisk has purchased three of Catalent’s fill-finish facilities from Novo Holdings. Credit: © 2024 Novo Nordisk A/S. Novo Holdings has completed the ...
This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...
Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback